News Release Details

A.P. Pharma to Hold Third Quarter 2001 Conference Call Nov. 6, 2001

10/31/2001 |
REDWOOD CITY, Calif., Oct 31, 2001 (BUSINESS WIRE) -- A.P. Pharma Inc. (Nasdaq:APPA), a specialty pharmaceutical company, will release 2001 third quarter financial results prior to market open on Tuesday, Nov. 6, 2001.

Paul Goddard, chairman, Michael O'Connell, president and chief executive officer, and Gordon Sangster, chief financial officer, will be hosting an investment-community conference call beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on Tuesday, Nov. 6, 2001 to discuss the results and to answer questions.

To participate in the live call via telephone, call 800/618-9649. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 800/633-8284, and entering reservation number 19950333.

Individuals interested in listening to the conference call via the Internet may do so by visiting A replay will be available on the company's Web site for 14 days.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM).

Initial targeted areas of application for the company's drug delivery technology include pain management, inflammation, anti-adhesion and protein delivery applications. The company's product development programs are funded by royalties from topical products currently marketed by pharmaceutical partners and proceeds from the divestiture of its cosmeceutical product lines.

For further information visit the company's Web site at

A.P. Pharma Inc., Redwood City
Gordon Sangster, 650/366-2626
Lippert/Heilshorn & Associates
Bruce Voss or Martin Halsall (investor relations),
310/691-7100 or

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.